Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.
Xia H, Zhang H, Ruan Z, Zhang H, Sun L, Chen H, Zhou Y, Zhang L, Bian D, Zhu X, Zhang J, Sun F, Yu H, Song N, Liu X, Zhu Y, Zhang H, He W, Chen J, Yang J, Chen G, Xie S, Tang D, Zhang X, Duan L, Zhao D, Li Q, Zhang P, Jiang G.
Xia H, et al. Among authors: zhang l, zhang p, zhang j, zhang h, zhang x.
Signal Transduct Target Ther. 2024 Jun 14;9(1):145. doi: 10.1038/s41392-024-01861-w.
Signal Transduct Target Ther. 2024.
PMID: 38871690
Free PMC article.
Clinical Trial.